Oral Taxane in Combination With Pemetrexed (Alimta) in Patients With Recurrent Non-Small Cell Lung Cancer

Bristol-Myers Squibb

Overview

A phase I-II dose ranging study of BMS-275183 (oral taxane) in combination with pemetrexed (Alimta) in patients with recurrent Non-Small Cell Lung Cancer (NSCLC). The safety and efficacy of this combination will be studied.

Study Type

INTERVENTIONAL

Purpose

TREATMENT

Conditions

Non-small Cell Lung Cancer

Interventions

Oral TaxaneDRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Advanced or metastatic pretreated NSCLC * Measurable disease * Adequate hematologic, hepatic and renal functions. * ECOG Performance Status 0-2 Exclusion Criteria: * Inability to swallow capsules * Recent significant cardiovascular disease * Women who are pregnant or breastfeeding

Locations (3)

Local Institution

Denver, Colorado, United States

Local Institution

Rochester, Minnesota, United States

Local Institution

Toronto, Ontario, Canada

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.